Retina

Subramanian discusses how subtle retinal and optic nerve findings can point to underlying neurologic disease.

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.

Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.

EyeArt uses artificial intelligence for autonomous detection of vision-threatening diabetic retinopathy

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The partnership was announced in August of this year.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

We ask leading experts in the field what eye disease they would cure and why.

At the EURETINA congress, Prof Boon discussed controversies in treatment, some driven by critical prospective studies

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025

We ask leading experts in the field what eye disease they would cure and why.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.